Drugs / FLOTUFOLASTAT

Trials 4 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT07149831 Jun → Dec 2025 overdue prostate cancer Sinotau Pharmaceutical Group Recruiting No outcome recorded
Phase 22 trials
Phase 2 NCT07220720 Nov 2025 → Jul 2030 expected prostate cancer University of Florida Recruiting No outcome recorded
Phase 2 NCT07185165 Oct 2025 → Oct 2035 expected prostate carcinoma Jonsson Comprehensive Cancer Center Recruiting No outcome recorded
Phase 41 trial
Phase 4 NCT06604442 Dec 2024 → Aug 2025 prostate cancer Blue Earth Diagnostics Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT06881823 Comparator Jun 2026 → Mar 2030 prostate cancer Novartis Pharmaceuticals Withdrawn No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as FLOTUFOLASTAT ChEMBL registry synonym — accepted as the source's own label CHEMBL5316155
Known as 18F-rhPSMA-7.3 “PSMA-PET radiopharmaceuticals, 18F-piflufolastat (18F-DCFPyL) and 18F-flotufolastat (18F-rhPSMA-7.3) in patients with biochemical recurrence (BCR) of prostate cancer” PMID 41729277 Feb 2026
Known as flotufolastat (18F) ClinicalTrials.gov intervention name — accepted as the source's own label NCT06604442
Known as flotufolastat F 18 Flotufolastat F 18 is a radioactive tracer that binds to prostate specific membrane antigen (PSMA), a protein over-expressed on prostate tumor cells.” NCT07185165
3

NCT06881823

NCT07149831

NCT07220720

Known as fluorine F 18 flotufolastat “To evaluate the accuracy of fluorine F 18 flotufolastat (flotufolastat F 18) compared with prostate biopsy to determine treatment success following focal therapy of the prostate.” NCT07185165
1

NCT07185165

Known as rhPSMA-7.3C ChEMBL registry synonym — accepted as the source's own label CHEMBL5316155
Modality Diagnostic / imaging agent “positron emission tomography (PET) imaging tracer” NCT07149831
Route Intravenous “Subjects will receive 5.47\~6.69mCi of Flotufolastat F-18 Injection via IV injection.” NCT07149831